Abstract 298: Amplification of mutant ERBB2 drives resistance to the irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer patients von Carmona, F Javier, Hyman, David, Ulaner, Gary, Erinjeri, Joe, Bouvier, Nancy, Won, Helen, Cutler, Richard, Alani, Al, Berger, Michael, Baselga, José, Scaltriti, Maurizio

Volltext

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Stu... von Diamond, Eli L., Subbiah, Vivek, Lockhart, Craig, Blay, Jean-Yves, Faris, Jason E., Puzanov, Igor, Chau, Ian, Raje, Noopur S., Wolf, Jürgen S., Erinjeri, Joe, Torrisi, Jean, Ulaner, Gary, Lacouture, Mario, Robson, Susan, Makrutzki, Martina, Elez, Elena, Tabernero, Josep, Abdel-Wahab, Omar, Baselga, Jose, Hyman, David M.

Volltext